Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 501–600 of 3,959
Passanisi, S., Lombardo, F., Mameli, C., Bombaci, B., Macedoni, M., Zuccotti, G., Dovč, K., Battelino, T., Salzano, G., & Delvecchio, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01501-6 · Cited by 46
“In all the studies, the time below range was within the clinically recommended targets [42] and not significantly different compared to baseline (at which time it was already at target), suggesting that, even if the system is more aggressive than the first-generation AID systems in its glucose…”
BackgroundSelf-citationTime in Tight Range for Patients With Type 1 Diabetes: The Time Is Now, or Is It Too Soon?
Hamidi, V., & Pettus, J. (2024) · Diabetes Care · doi:10.2337/dci23-0092 · Cited by 38
Bode, B. W., Garg, S. K., Norwood, P. C., Morales, C., Hardy, T. A., Liu, R., & Ignaut, D. A. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0224 · Cited by 34
Self-citationType 1 Diabetes: Management in Women From Preconception to Postpartum
Buschur, E., & Polsky, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa931 · Cited by 36
Gómez, A. M., Henao, D. C., Parra, D., Kerguelen, A., Pinilla, M. V., Múñoz, Ó., & Rondón, M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.12.041 · Cited by 34
“HCL has demonstrated increased time in range and reductions in A1c, hyperglycemia and hypoglycemia [1].”
Barua, S., Sabharwal, A., GLANTZ, N. M., Conneely, C., LAREZ, A. J., Bevier, W. C., & Kerr, D. E. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100853 · Cited by 36
“Specifically, CGM provides a variety of glycemic metrics that can be used to set glycemic targets, guide therapeutic decision making, and potentially supplement HbA1c as a measure of glycemic status for people living with diabetes [2].”
BackgroundMethodInfluentialLandstra, C. P., Andrès, A., Chetboun, M., Conte, C., Kelly, Y. M., Berney, T., de Koning, E. J. P., Piemonti, L., Stock, P. G., Pattou, F. N., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab386 · Cited by 38
Adolfsson, P., Björnsson, V., Hartvig, N. V., Kaas, A., Møller, J. B., & Lange, E. O. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01177-w · Cited by 43
“A 5% increase in TIR was considered to be associated with clinically significant benefits [21].”
BackgroundCystic fibrosis-related diabetes: Prevalence, screening, and diagnosis
Khare, S., Desimone, M. E., Kasim, N. R., & Chan, C. L. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100290 · Cited by 50
“International consensus for CGM data interpretation and time in range (TIR) were published for type 1 and type 2 diabetes and different criteria may be more appropriate for CFRD [50].”
BackgroundKobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
Arunachalum, S., Velado, K., Vigersky, R. A., & Cordero, T. L. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088608 · Cited by 34
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro
Heise, T., de Oliveira, C. P., Juneja, R., Ribeiro, A., Chigutsa, F. B., & Blevins, T. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14773 · Cited by 38
“Currently, the quality of glycaemic control is not only indicated by HbA1c, but also by continuous glucose monitoring (CGM) metrics such as time in range (TIR), time below range (TBR) and time above range (TAR), which help to elucidate potential areas for glycaemic improvement.(8-10) Postprandial glucose (PPG) is know…”
BackgroundClinical application guidelines for blood glucose monitoring in China (2022 edition)
Bao, Y., Zhu, D., & Chinese Diabetes Society (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3581 · Cited by 42
“The international TIR consensus recommended the ambulatory Glucose Profile (AGP) as the standardised reporting form for CGM data.(66) AGP aggregates glucose data over multiple days into a 24‐h mode.”
BackgroundMethodInfluentialHaidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jafar, A., Devaux, M., Ghanbari, M., & RABASA-LHORET, R. P. R. (2023) · Diabetes Care · doi:10.2337/dc22-2297 · Cited by 46
“This 4% margin is also lower than the international consensus limit of 5% as a clinically meaningful difference in target range (23), though newer international guidelines, published after the design of this study, call for investigators to power studies to detect a minimum of 3% change in time in target range (24).”
BackgroundHeart Rate Variability for the Early Detection of Cardiac Autonomic Dysfunction in Type 1 Diabetes
Castiglioni, P., Faini, A., Nys, A., Busser, R. D., Scherrenberg, M., Baldussu, E., Parati, G., & Dendale, P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.937701 · Cited by 41
“HRV could also help identify candidates for more stringent glycemic control with continuous glucose monitoring devices and insulin pumps (Battelino et al., 2019).”
BackgroundContinuous Glucose Monitoring to Optimize Management of Diabetes in Patients with Advanced CKD
Galindo, R. J., de Boer, I. H., Neumiller, J. J., & Tuttle, K. R. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04510422 · Cited by 36
Messer, L. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0308 · Cited by 37
“The dependent variables were chosen per the consensus CGM outcomes 11 and the predictors included age (years), number of user-given boluses per day, relative TDI (U/kg), C:I ratio TDI index, Correction Factor TDI index, and Basal program TDI fraction.”
MethodKey indices of glycaemic variability for application in diabetes clinical practice
Monnier, L., Bonnet, F., Colette, C., Renard, É., & Owens, D. R. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101488 · Cited by 36
Kovatchev, B. P., Castillo, A., Pryor, E. C., Kollar, L. L., Barnett, C. L., DeBoer, M. D., Brown, S. A., & for the NAP Study Team (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0469 · Cited by 46
Self-citationKovatchev, B. P., Lobo, B. J., Fabris, C., Ganji, M., Fathi, A. E., Breton, M. D., Kanapka, L. G., Kollman, C., Battelino, T., & Beck, R. W. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0404 · Cited by 37
“Sensitivity analysis showed that 14 days of CGM, that is, a standard ambulatory glucose pro fi le, 7,21 appeared suf fi - cient to capture the progression of microvascular complications with relevant clinical implications.”
Self-citationCalliari, L. E., Krakauer, M., Vianna, A. G. D., Ram, Y., Barbieri, D. E., Xu, Y., & Dunn, T. C. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0513-z · Cited by 40
“patients the correlations are weaker for hypoglycemia and glycemic variability, thus confirming that these two metrics are more challenging to interpret [8].”
BackgroundPleus, S., Kamecke, U., Waldenmaier, D., Link, M., Zschornack, E., Jendrike, N. R. M., Haug, C., & Freckmann, G. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820931825 · Cited by 34
Lim, M. H., Lee, W. H., Jeon, B., & Kim, S. (2021) · IEEE Access · doi:10.1109/access.2021.3100007 · Cited by 47
Ekberg, N. R., Hartvig, N. V., Kaas, A., Møller, J. B., & Adolfsson, P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221104142 · Cited by 36
“23 In contrast, missed bolus insulin doses were associated with changes in glycemic variability and, as such, a reduced TIR.”
BackgroundBenhamou, P., Adenis, A., Tourki, Y., Pou, S., Madrolle, S., Franc, S., Kariyawasam, D., Beltrand, J., Klonoff, D. C., & Charpentier, G. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221128565 · Cited by 33
“We selected all patients staying more than 5% in hypoglycaemia, this threshold being proposed by the International Consensus on CGM data 6,7 and meaning more than 72 minutes per day below the 70 mg/dL level.”
MethodStentebjerg, L. L., Madsen, L. R., Støving, R. K., Andersen, L. L. T., Vinter, C. A., Juhl, C. B., & Jensen, D. M. (2022) · Diabetes Care · doi:10.2337/dc22-1357 · Cited by 37
“Adapted from the international consensus on glucose targets in pregnancy with type 1 diabetes, because no target values exist on glucose range in pregnancies after RYGB (21).”
BackgroundInfluentialDiscordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without Diabetes
Shah, V. N., Vigers, T., Pyle, L. L., Calhoun, P. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0544 · Cited by 41
Self-citationTatulashvili, S., Baptiste Julla, J., Sritharan, N., Rezgani, I., Levy, V., Bihan, H., Riveline, J.-P., & Cosson, E. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac443 · Cited by 33
Kalra, S., Shaikh, S. S., Priya, G., Baruah, M., Verma, A., Das, A. K., Shah, M., Das, S., Khandelwal, D., Sanyal, D., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00973-0 · Cited by 37
Self-citationClinical Application of Time in Range and Other Metrics
Aleppo, G. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0093 · Cited by 35
Cai, J., Yang, Q., Lu, J., Shen, Y., Wang, C., Chen, L., Zhang, L., Lu, W., Zhu, W., Xia, T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac692 · Cited by 35
Nwokolo, M., Lakshman, R., Hartnell, S., Alwan, H., Ware, J., Allen, J. M., Wilinska, M. E., Evans, M. L., Hovorka, R., & Boughton, C. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0262 · Cited by 34
“14 Time spent in hypoglycemia in this study was low for both ultra-rapid lispro and standard lispro, and within the ranges recommended by international consensus guidance on time in range 21 during closed-loop study periods.”
Self-citationSmart Hydrogel Micromechanical Resonators with Ultrasound Readout for Biomedical Sensing
Farhoudi, N., Leu, H.-Y., Laurentius, L. B., Magda, J. J., Solzbacher, F., & Reiche, C. F. (2020) · ACS Sensors · doi:10.1021/acssensors.9b02180 · Cited by 32
Gal, R. L., Cohen, N. J., Kruger, D., Beck, R. W., Bergenstal, R. M., Calhoun, P., Cushman, T., Haban, A., Hood, K., Johnson, M. L., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa076 · Cited by 32
“0 mmol/L), which is the generally accepted target range for most adults with T1D or T2D (excluding pregnancy) [27].”
BackgroundSelf-citationCurrent and Future Roles of Consumer Sleep Technologies in Sleep Medicine
Goldstein, C. A. (2020) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2020.05.001 · Cited by 35
Danne, T., Schweitzer, M. A., Keuthage, W., Kipper, S., Kretzschmar, Y., Simon, J., Wiedenmann, T., & Ziegler, R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0360 · Cited by 33
Self-citationSheng, X., Xiong, G., Yu, P., & Liu, J.-P. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8879085 · Cited by 35
MOSQUERA-LOPEZ, C. M., & Jacobs, P. G. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211042621 · Cited by 44
“28 The primary performance outcome measure was the RMSE that represents the second sample moment of the prediction residuals (equation (2)).”
BackgroundBlood Glucose Monitoring in Adults and Children with Diabetes: Update 2021
CHENG, A. Y. Y., Feig, D. S., Ho, J., Siemens, R. L., BAJAJ, H. S., Gilbert, J. D., Houlden, R. L., Kim, J., MacKay, D., Rabi, D. M., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.07.003 · Cited by 40
Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus
Pintaudi, B., Gironi, I., Nicosia, R., Meneghini, E., Disoteo, O., Mion, E., & Bertuzzi, F. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.03.031 · Cited by 32
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
Nowak, C., Lind, M., Šumník, Z., Pelikánová, T., Nattero‐Chávez, L., Lundberg, E., Rica, I., Martínez‐Brocca, M. A., de Adana, M. R., Wahlberg, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac343 · Cited by 39
“Both the American Diabetes Association (11) and an international consensus (12) recommend the use of time in range (time in range [TIR], 3.”
BackgroundBassi, M., Patti, L., Silvestrini, I., Strati, M. F., Ponzano, M., Minuto, N., & Maggi, D. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1099024 · Cited by 37
A new continuous glucose monitor for the diagnosis of gestational diabetes mellitus: a pilot study
Filippo, D. D., Henry, A., Bell, C., Haynes, S., Chang, M. H. Y., Darling, J., & Welsh, A. W. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05496-7 · Cited by 34
“Of promise is Continuous Glucose Monitoring (CGM), which allows for evaluation of interstitial glucose levels during up to 14 days of ordinary life, as opposed to a oneoff response to an artificial glucose load, offering a completely new perspective on glucose homeostasis [7].”
BackgroundBeato-Víbora, P. I. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0184 · Cited by 33
RetractedHypoglycemia event prediction from CGM using ensemble learning
Fleischer, J., Hansen, T. K., & Cichosz, S. L. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.1066744 · Cited by 37
“Hypoglycemia was defined as CGM values below 70 mg/dL for 15 minutes or more (sustained hypoglycemia) – the definition was based on the recommendations in previous studies (19, 20).”
MethodIgudesman, D., Crandell, J. L., Corbin, K. D., Hooper, J., Thomas, J. M., Bulik, C. M., Pence, B. W., Pratley, R. E., Kosorok, M. R., Maahs, D. M., et al. (2023) · The Journal of Nutrition · doi:10.1016/j.tjnut.2022.12.017 · Cited by 32
Prasad‐Reddy, L., Godina, A., Chetty, A. K., Close Concerns, S. F., & Isaacs, D. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.116 · Cited by 42
Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice
Chirila, A., Nguyen, M. E., Tinmouth, J., & Halperin, I. J. (2022) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwac035 · Cited by 36
Jacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A. X., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 40
Self-citationJENDLE, J. H., Adolfsson, P., Choudhary, P., Dovč, K., Fleming, G. A., Klonoff, D. C., Mader, J. K., Oliver, N. S., Sherr, J. L., Šoupal, J., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06049-5 · Cited by 33
“Open access to data, while complying with the General Data Protection Regulation (GDPR), which came into effect in the EU in 2018, would also support data analysis, data interpretation and display of data in a clear and instructive manner [3].”
MethodSelf-citationSøholm, U., Broadley, M. M., Zaremba, N., Divilly, P., Baumann, P. M., MAHMOUDI, Z., Martine‐Edith, G., Mader, J. K., Cigler, M., Brøsen, J. M. B., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06233-1 · Cited by 39
“…PRH: episodes considered treated • Other PRH: episodes considered neither prevented nor treated Finally, following the ATTD consensus guidelines [19], the CGM data from the blinded sensors was used to classify each time interval into the following SDH subtypes: • No SDH: no SDH captured with…”
Self-citationConsensus Report on the Use of Continuous Glucose Monitoring in Chronic Kidney Disease and Diabetes
Rhee, C. M., Gianchandani, R. Y., Kerr, D. E., Philis‐Tsimikas, A., Kovesdy, C. P., Stanton, R. C., Drincic, A., Galindo, R. J., Kalantar‐Zadeh, K., Neumiller, J. J., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241292041 · Cited by 40
“Target percentages of time can be extrapolated from the 2019 International Consensus on Time in Range Report 65 for high-risk patients (defined as older patients as well as others at high risk of severe hypoglycemia, including those with kidney disease).”
Visser, H. S. D., Waraich, S., Chhabra, M., Yamamoto, J. M., Zenlea, I. S., Askin, N., Rabbani, R., McGavock, J., TEAM Trial Patient Coresearchers, Greenberg, D. T., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2740 · Cited by 44
Factors Influencing Insulin Absorption Around Exercise in Type 1 Diabetes
Pitt, J. P., McCarthy, O. M., Høeg-Jensen, T., Wellman, B., & Bracken, R. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573275 · Cited by 38
Gubitosi-Klug, R. A., Braffett, B. H., Bebu, I., Johnson, M. L., Farrell, K., Kenny, D., Trapani, V. R., Meadema-Mayer, L., Soliman, E. Z., Pop-Busui, R., et al. (2022) · Diabetes Care · doi:10.2337/dc21-0629 · Cited by 31
Self-citationGoyal, A., Gupta, Y., & Tandon, N. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01210-6 · Cited by 43
“For pregnant women with type 2 diabetes and overt diabetes/GDM, target range is similar; however, the percentage of time in range has not been defined because of the lack of adequate evidence [50].”
BackgroundRossi, A., Venema, A., Haarsma, P., Feldbrugge, L., Burghard, R., Rodriguez‐Buritica, D., Parenti, G., Oosterveer, M. H., & Derks, T. G. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac411 · Cited by 35
Professional Competencies for Diabetes Technology Use in the Care Setting
Patil, S. P., Albanese-O’Neill, A., Yehl, K., Seley, J. J., & Hughes, A. S. (2022) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106221120889 · Cited by 31
Molfetta, S. D., Caruso, I., Cignarelli, A., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14981 · Cited by 36
Šantová, A., Plachý, L., Neuman, V., Pavlı́ková, M., Petruželková, L., Konečná, P., Venháčová, P., Škvor, J., Pomahačová, R., Neumann, D., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1283181 · Cited by 32
Beunen, K., Wilder, N. V., Ballaux, D., Vanhaverbeke, G., Taes, Y., Aers, X.-P., Nobels, F. R. E., Marlier, J., Lee, D. Y., Cuypers, J., et al. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05481-0 · Cited by 34
“8 mmol/L (63–140 mg/dL) of > 70% [5].”
Self-citationPrioleau, T., Bartolome, A., Comi, R. J., & Stanger, C. (2023) · Scientific Data · doi:10.1038/s41597-023-02469-5 · Cited by 54
“For each patient included in the DiaTrend dataset, we provide an overview of their blood glucose data using clinically-validated metrics for assessing glycemic control 54,55 .”
BackgroundMethodKumbara, A. B., Iyer, A. K., Green, C. R., Jepson, L. H., Leone, K., Layne, J. E., & Shomali, M. (2023) · JMIR Diabetes · doi:10.2196/47638 · Cited by 29
Kusinski, L. C., Jones, D., Atta, N., Turner, E., Smith, S., Oude Griep, L. M., Rennie, K., De Lucia Rolfe, E., Sharp, S. J., Farewell, V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03356-1 · Cited by 30
Self-citationCordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., McVean, J., Lee, S. W., Slover, R. H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0123 · Cited by 30
Self-citationSilva, R. R. E., Gauza, M. D. M., Guisso, M. E. S., da Silva, J. O. N., & Kohara, S. K. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000614 · Cited by 33
“The recommended mean TIR by the International Consensus is > 70% (13).”
BackgroundNkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01468-4 · Cited by 42
“Time in range (TIR), which is defined as the percentage of time that blood glucose is between 3.9 and 10.0 mmol/L [83, 84], is a clinically relevant indicator of glycemic management that is inversely correlated with HbA1c [85].”
BackgroundInfluentialAiello, E. M., Jaloli, M., & Cescon, M. (2023) · Control Engineering Practice · doi:10.1016/j.conengprac.2023.105810 · Cited by 37
Herz, D., Karl, S., Weiß, J., Zimmermann, P., Haupt, S., Zimmer, R. T., Schierbauer, J., Wachsmuth, N. B., Erlmann, M. P., Niedrist, T., et al. (2024) · Nutrients · doi:10.3390/nu16081114 · Cited by 37
“The participants used the app to record their food intake by scanning barcodes or searching the database, recording the quantities consumed, and the times of consumption.”
MethodAjjan, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16098 · Cited by 40
Carlson, A. L., Criego, A. B., Martens, T. W., & Bergenstal, R. M. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.010 · Cited by 33
Self-citationBenefits and limitations of continuous glucose monitoring in type 1 diabetes
Stone, J. Y., & Bailey, T. S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1706482 · Cited by 30
“Guidelines for interpretation of CGM data have been published to aid clinicians and PWD in establishing clinical targets for glycemic control [36,37].”
MethodPetrovski, G., Khalaf, F. A., Campbell, J., Fisher, H., Umer, F., & Hussain, K. (2020) · Acta Diabetologica · doi:10.1007/s00592-019-01472-w · Cited by 32
Short Term Blood Glucose Prediction based on Continuous Glucose Monitoring Data
Mohebbi, A., Johansen, A. R., Hansen, N., Christensen, P. E., Tarp, J. M., Jensen, M. L., Bengtsson, H. L., & Mørup, M. (2020) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc44109.2020.9176695 · Cited by 47
“Inspired by the international CGM consensus, only CGM days and periods with more than 70% available BG readings are included [3].”
BackgroundMethodAssessment of Glucose Control Metrics by Discriminant Ratio
Moscardó, V., Herrero, P., Reddy, M., Hill, N. R., Georgiou, P., & Oliver, N. S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0415 · Cited by 33
Cutruzzolà, A., Irace, C., Parise, M., Fiorentino, R., Tripodi, P. F. P., Ungaro, S., Babinsky, V. N., & Gnasso, A. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.06.009 · Cited by 32
Freckmann, G., Pleus, S., Schauer, S., Link, M., Jendrike, N. R. M., Waldenmaier, D., Haug, C., & Stuhr, A. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1347-2550 · Cited by 31
Kim, M. Y., Kim, G., Park, J. Y., Choi, M. S., Jun, J. E., Lee, Y.-B., Jin, S.-M., Hur, K. Y., & Kim, J. H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0599 · Cited by 30
Lv, W., Zhong, Q., Guo, J., Luo, J., Dixon, J. K., & Whittemore, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073450 · Cited by 33
“5% for youths (aged under 18) which are the care goals for people with T1D [42].”
BackgroundEvidence of Early Diabetic Nephropathy in Pediatric Type 1 Diabetes
Mamilly, L., Mastrandrea, L. D., Vasquez, C. M., Klamer, B. G., Kallash, M., & Aldughiem, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.669954 · Cited by 31
Cherubini, V., Rabbone, I., Berioli, M. G., Giorda, S., Presti, D. L., Maltoni, G., Mameli, C., Marigliano, M., Marino, M., Minuto, N., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14491 · Cited by 30
“Δ % time 70-180 mg/dL 14 (10; 18) 6 (2; 8) .”
The automated pancreas: A review of technologies and clinical practice
Biester, T., Tauschmann, M., Chobot, A. P., Kordonouri, O., Danne, T., Kapellen, T. M., & Dovč, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14576 · Cited by 34
“should be spent in the hypoglycaemic range <70 mg/dL, that is, less than 1 hour per day.(105) To avoid severe hypoglycaemic events, values <54 mg/dL should occur less than 1% of the time.”
BackgroundSelf-citationLee, J. M., Rusnak, A., Garrity, A., Hirschfeld, E., Thomas, I. H., Wichorek, M., Lee, J. E., Rioles, N. A., Ebekozien, O., & Corathers, S. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.31278 · Cited by 30
Marigliano, M., Eckert, A. J., Guness, P. K., Herbst, A., Smart, C. E., Witsch, M., Maffeis, C., & SWEET Study Group (2021) · Pediatric Diabetes · doi:10.1111/pedi.13274 · Cited by 37
“The increased use of CGM modified the management of T1D in these patients improving glycemic control and reducing glycemic variability.(20,24,27,28,30) Moreover, recent international guidelines recommend early adoption of CGM for all children and adolescents with T1D.”
MethodArias-Córdova, Y., Blé‐Castillo, J. L., García-Vázquez, C., Olvera‐Hernández, V., Ramos-García, M., Navarrete-Cortes, A., Jiménez-Domínguez, G., Juárez‐Rojop, I. E., Tovilla‐Zárate, C. A., Martínez‐López, M. C., et al. (2021) · Nutrients · doi:10.3390/nu13114052 · Cited by 39
“TAR was defined as the percent time with glucose levels above 180 mg/dL; TIR was defined as the percent time with glucose levels between 70 mg/dL and 180 mg/dL; and TBR was defined as the percent time with glucose levels less than 70 mg/dL [17].”
Karakus, K. E., Sakarya, S., Mutlu, G. Y., Berkkan, M., Muradoğlu, S., Can, E., Gökçe, T., Eviz, E., & Hatun, Ş. (2021) · Journal of Patient Experience · doi:10.1177/23743735211056523 · Cited by 39
“However, it is seen that the families are not aware of “time in range centered diabetes care” approach that has been on the T1D agenda in recent years (18,19).”
BackgroundAntoniotti, V., Spadaccini, D., Ricotti, R., Carrera, D., Savastio, S., Correia, F. P. G., Caputo, M., Pozzi, E., Bellone, S., Rabbone, I., et al. (2022) · Nutrients · doi:10.3390/nu14030596 · Cited by 36
“5% and TIR lower than 70%, two validated cut-offs that represented approximately one-third of each group [22].”
BackgroundContinuous Glucose Monitoring for the Diagnosis of Gestational Diabetes Mellitus: A Pilot Study
Filippo, D. D., Ahmadzai, M., Chang, M. H. Y., Horgan, K., Ong, R. M., Darling, J., Akhtar, M., Henry, A., & Welsh, A. W. (2022) · Journal of Diabetes Research · doi:10.1155/2022/5142918 · Cited by 34
“Glycaemic targets for GDM women are stricter than those for type one diabetic patients and the general population, although little evidence has been reported so far on GDM tailored thresholds [33].”
BackgroundShah, V. N., Sakamoto, C., & Pyle, L. L. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0401 · Cited by 30
Márquez-Pardo, R., Torres-Barea, I., Córdoba-Doña, J.-A., Cruzado-Begines, C., García-García-Doncel, L., Aguilar-Diosdado, M., & Baena-Nieto, M.-G. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0319 · Cited by 29
Al‐Sofiani, M. E., Petrovski, G., Shaikh, A. A., Alguwaihes, A. M., Harbi, M. A., Mohannadi, D. A., Adjene, A., Al-Agha, A. E., Remeithi, S. S. A., Alamuddin, N., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15389 · Cited by 30
“12 Furthermore, the study also demonstrated that younger individuals in the subgroup aged ≤ 15 years, who may not adhere to fasting, still exhibited safe and satisfactory glycemic control.”
Pai, A., Santiago, R., GLANTZ, N. M., Bevier, W. C., Barua, S., Sabharwal, A., & Kerr, D. E. (2024) · npj Digital Medicine · doi:10.1038/s41746-023-00985-7 · Cited by 36
“Towards that, current approaches have mainly analyzed continuous glucose data and focused on aggregate measures of glycemic control over longer durations, e.g., time-in-range and glycemic variability over 2 weeks 7 .”
Tan, Y. Y., Suan, E., Koh, G. C. H., Suhairi, S. B., & Tyagi, S. (2024) · Archives of Public Health · doi:10.1186/s13690-024-01459-2 · Cited by 35
Use of Diabetes Technology in Children
Desrochers, H. R., Schultz, A. T., & Laffel, L. M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.11.001 · Cited by 29
Self-citationAssociation of time in range with hemoglobin A1c, glycated albumin and 1,5‐anhydro‐ d ‐glucitol
Ohigashi, M., Osugi, K., Kusunoki, Y., Washio, K., Matsutani, S., Tsunoda, T., Matsuo, T., Konishi, K., Katsuno, T., Namba, M., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13437 · Cited by 33
Barchetta, I., Cimini, F. A., Bertoccini, L., Ceccarelli, V., Spaccarotella, M., Baroni, M. G., & Cavallo, M. G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108513 · Cited by 29
“The study’s primary outcomewas the change of blood glucose (BG) time in range (TIR; 70–180 mg/dl, %) [4] from prelockdown to lockdown period.”
Ilesanmi, I., Tharakan, G., Αλεξιάδου, Κ., Behary, P., Alessimii, H., Bovill-Taylor, C., Kenkre, J. S., Choudhury, S., Doyle, C., Purkayastha, S., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1609 · Cited by 35
Babaya, N., Noso, S., Hiromine, Y., Taketomo, Y., Niwano, F., Yoshida, S., Yasutake, S., Kawabata, Y., & Ikegami, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-83599-x · Cited by 38
Varghese, J. S., Ho, J. C., Anjana, R. M., Pradeepa, R., Patel, S. A., Jebarani, S., Baskar, V., Narayan, K. M. V., & Mohan, V. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0672 · Cited by 36
Dave, D., Erraguntla, M., Lawley, M., DeSalvo, D. J., Haridas, B., McKay, S. V., & Koh, C. J. (2021) · JMIR Diabetes · doi:10.2196/26909 · Cited by 30
“76% [1368/6010] of the events) based on the recommendations in previous studies [51,52].”
Background
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.